Sparrow Pharmaceuticals Inc.

4 trials Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

5 Completed trials

4 Countries active

3 Unique IMPs

100% Results reported

Phase II

Phase I (Other)

Phase II: 3 Phase I (Other): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Polymyalgia rheumatica 2 Pituitary-dependent Cushing´s syndrome 1

Top IMPs

CLOFUTRIBEN 2 4-{5-[2-(4-CHLORO-2,6-DIFLUOROPHENOXY)PROPAN-2-YL]-4-METHYL-4H-1,2,4-TRIAZOL-3-YL}-3-FLUOROBENZAMIDE 1 PREDNISOLONE 1

All trials

4 total

SPI-62 as a treatment for adrenocorticotropic hormone-dependent Cushing’s syndrome Ended

2024-515913-17-00 Phase II 2 countries CLOFUTRIBEN
A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR) Ended

2023-507721-41-00 Phase I (Other) 1 country
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR) Ended

2024-517406-29-00 Phase II 2 countries CLOFUTRIBEN; PREDNISOLONE
"SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor " Ended

2024-516785-12-00 Phase II 1 country 4-{5-[2-(4-CHLORO-2,6-DIFLUOROPHENOXY)PROPAN-2-YL]-4-METHYL-4H-1,2,4-TRIAZOL-3-Y…

Showing 1–4 of 4 trials

← All sponsors A–Z